380 related articles for article (PubMed ID: 18430084)
1. A novel autotransporter of uropathogenic Proteus mirabilis is both a cytotoxin and an agglutinin.
Alamuri P; Mobley HL
Mol Microbiol; 2008 May; 68(4):997-1017. PubMed ID: 18430084
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with proteus toxic agglutinin, a hemolysin-independent cytotoxin in vivo, protects against Proteus mirabilis urinary tract infection.
Alamuri P; Eaton KA; Himpsl SD; Smith SN; Mobley HL
Infect Immun; 2009 Feb; 77(2):632-41. PubMed ID: 19029299
[TBL] [Abstract][Full Text] [Related]
3. Identification of protease and rpoN-associated genes of uropathogenic Proteus mirabilis by negative selection in a mouse model of ascending urinary tract infection.
Zhao H; Li X; Johnson DE; Mobley HLT
Microbiology (Reading); 1999 Jan; 145 ( Pt 1)():185-195. PubMed ID: 10206698
[TBL] [Abstract][Full Text] [Related]
4. Adhesion, invasion, and agglutination mediated by two trimeric autotransporters in the human uropathogen Proteus mirabilis.
Alamuri P; Löwer M; Hiss JA; Himpsl SD; Schneider G; Mobley HL
Infect Immun; 2010 Nov; 78(11):4882-94. PubMed ID: 20805336
[TBL] [Abstract][Full Text] [Related]
5. Proteus mirabilis genes that contribute to pathogenesis of urinary tract infection: identification of 25 signature-tagged mutants attenuated at least 100-fold.
Burall LS; Harro JM; Li X; Lockatell CV; Himpsl SD; Hebel JR; Johnson DE; Mobley HL
Infect Immun; 2004 May; 72(5):2922-38. PubMed ID: 15102805
[TBL] [Abstract][Full Text] [Related]
6. Use of green fluorescent protein to assess urease gene expression by uropathogenic Proteus mirabilis during experimental ascending urinary tract infection.
Zhao H; Thompson RB; Lockatell V; Johnson DE; Mobley HL
Infect Immun; 1998 Jan; 66(1):330-5. PubMed ID: 9423875
[TBL] [Abstract][Full Text] [Related]
7. Proteus mirabilis uroepithelial cell adhesin (UCA) fimbria plays a role in the colonization of the urinary tract.
Pellegrino R; Scavone P; Umpiérrez A; Maskell DJ; Zunino P
Pathog Dis; 2013 Mar; 67(2):104-7. PubMed ID: 23620155
[TBL] [Abstract][Full Text] [Related]
8. Flagellate and non-flagellate Proteus mirabilis in the development of experimental urinary tract infection.
Zunino P; Piccini C; Legnani-Fajardo C
Microb Pathog; 1994 May; 16(5):379-85. PubMed ID: 7815921
[TBL] [Abstract][Full Text] [Related]
9. The type III secretion system of Proteus mirabilis HI4320 does not contribute to virulence in the mouse model of ascending urinary tract infection.
Pearson MM; Mobley HLT
J Med Microbiol; 2007 Oct; 56(Pt 10):1277-1283. PubMed ID: 17893161
[TBL] [Abstract][Full Text] [Related]
10. Preventive and therapeutic administration of an indigenous Lactobacillus sp. strain against Proteus mirabilis ascending urinary tract infection in a mouse model.
Fraga M; Scavone P; Zunino P
Antonie Van Leeuwenhoek; 2005 Jul; 88(1):25-34. PubMed ID: 15928974
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis of
Armbruster CE; Mobley HLT; Pearson MM
EcoSal Plus; 2018 Feb; 8(1):. PubMed ID: 29424333
[No Abstract] [Full Text] [Related]
12. UreR, the transcriptional activator of the Proteus mirabilis urease gene cluster, is required for urease activity and virulence in experimental urinary tract infections.
Dattelbaum JD; Lockatell CV; Johnson DE; Mobley HL
Infect Immun; 2003 Feb; 71(2):1026-30. PubMed ID: 12540589
[TBL] [Abstract][Full Text] [Related]
13. Involvement of polyphosphate kinase in virulence and stress tolerance of uropathogenic Proteus mirabilis.
Peng L; Jiang Q; Pan JY; Deng C; Yu JY; Wu XM; Huang SH; Deng XY
Med Microbiol Immunol; 2016 Apr; 205(2):97-109. PubMed ID: 26233310
[TBL] [Abstract][Full Text] [Related]
14. Requirement of MrpH for mannose-resistant Proteus-like fimbria-mediated hemagglutination by Proteus mirabilis.
Li X; Johnson DE; Mobley HL
Infect Immun; 1999 Jun; 67(6):2822-33. PubMed ID: 10338487
[TBL] [Abstract][Full Text] [Related]
15. Complete genome sequence of uropathogenic Proteus mirabilis, a master of both adherence and motility.
Pearson MM; Sebaihia M; Churcher C; Quail MA; Seshasayee AS; Luscombe NM; Abdellah Z; Arrosmith C; Atkin B; Chillingworth T; Hauser H; Jagels K; Moule S; Mungall K; Norbertczak H; Rabbinowitsch E; Walker D; Whithead S; Thomson NR; Rather PN; Parkhill J; Mobley HL
J Bacteriol; 2008 Jun; 190(11):4027-37. PubMed ID: 18375554
[TBL] [Abstract][Full Text] [Related]
16. New aspects of RpoE in uropathogenic Proteus mirabilis.
Liu MC; Kuo KT; Chien HF; Tsai YL; Liaw SJ
Infect Immun; 2015 Mar; 83(3):966-77. PubMed ID: 25547796
[TBL] [Abstract][Full Text] [Related]
17. MrpJ Directly Regulates Proteus mirabilis Virulence Factors, Including Fimbriae and Type VI Secretion, during Urinary Tract Infection.
Debnath I; Stringer AM; Smith SN; Bae E; Mobley HLT; Wade JT; Pearson MM
Infect Immun; 2018 Oct; 86(10):. PubMed ID: 30082479
[No Abstract] [Full Text] [Related]
18. The high-affinity phosphate transporter Pst is a virulence factor for Proteus mirabilis during complicated urinary tract infection.
Jacobsen SM; Lane MC; Harro JM; Shirtliff ME; Mobley HL
FEMS Immunol Med Microbiol; 2008 Mar; 52(2):180-93. PubMed ID: 18194341
[TBL] [Abstract][Full Text] [Related]
19. Mannose-resistant Proteus-like and P. mirabilis fimbriae have specific and additive roles in P. mirabilis urinary tract infections.
Zunino P; Sosa V; Schlapp G; Allen AG; Preston A; Maskell DJ
FEMS Immunol Med Microbiol; 2007 Oct; 51(1):125-33. PubMed ID: 17854474
[TBL] [Abstract][Full Text] [Related]
20. Repression of bacterial motility by a novel fimbrial gene product.
Li X; Rasko DA; Lockatell CV; Johnson DE; Mobley HL
EMBO J; 2001 Sep; 20(17):4854-62. PubMed ID: 11532949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
